Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a rare genetic condition with no approved therapies.
The company reported that REC-4881 achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment. Notably, 82% of patients maintained durable reductions even 12 weeks after stopping therapy, with a 53% median reduction from baseline.
These results are particularly significant when compared to natural history data showing that 87% of untreated FAP patients typically experience increased polyp burden over time. The drug also demonstrated clinical benefit with 40% of patients achieving a clinically meaningful improvement in Spigelman stage, a measure of upper GI disease severity.
"The durable polyp burden reduction demonstrated by REC-4881—especially the sustained effect seen at Week 25, 12 weeks after completing therapy—is highly encouraging for the FAP community," said Jessica Stout, Principal Investigator of the TUPELO study and Assistant Clinical Professor at University of Utah School of Medicine.
REC-4881, an allosteric MEK1/2 inhibitor, was identified through Recursion’s artificial intelligence platform, the Recursion OS. The company noted that the safety profile was consistent with MEK1/2 inhibition, with most treatment-related adverse events being Grade 1 or 2, and no Grade 4 or higher events reported.
Recursion plans to engage with the FDA in the first half of 2026 to define a potential registration pathway while expanding the eligible patient population and optimizing the dosing schedule.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
